Arcus Biosciences Shares Drop 12% After Discontinuing Phase 3 STAR-221 Trial

Core Viewpoint - Arcus Biosciences, Inc. has announced the discontinuation of its Phase 3 STAR-221 study in collaboration with Gilead Sciences, leading to a significant drop in its stock price by 11.50 percent to $22.25 [1] Stock Performance - The stock opened at $21.15 and has fluctuated between $20.35 and $24.00 on the New York Stock Exchange [1] - Current trading volume stands at 4,426,823 shares, compared to an average volume of 1,561,846 shares [1] - Arcus shares are trading significantly below their recent peak, with a 52-week range of $6.50 to $26.40 [1]